Profound Medical Corp.
PROF · NASDAQ
9/30/2025 | 6/30/2025 | 3/31/2025 | 12/31/2024 | |
|---|---|---|---|---|
| Revenue | $5 | $2 | $3 | $5 |
| % Growth | 136.6% | -15.6% | -50.8% | – |
| Cost of Goods Sold | $1 | $1 | $1 | $2 |
| Gross Profit | $4 | $2 | $2 | $4 |
| % Margin | 74.3% | 73.2% | 70.7% | 68.1% |
| R&D Expenses | $5 | $6 | $5 | $7 |
| G&A Expenses | $0 | $0 | $0 | $12 |
| SG&A Expenses | $7 | $9 | $8 | $24 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $12 |
| Other Operating Expenses | $0 | $0 | $0 | $56 |
| Operating Expenses | $13 | $15 | $13 | $86 |
| Operating Income | -$9 | -$14 | -$11 | -$82 |
| % Margin | -168.5% | -624.4% | -426% | -1,548.3% |
| Other Income/Exp. Net | $1 | -$2 | $0 | $74 |
| Pre-Tax Income | -$8 | -$16 | -$11 | -$8 |
| Tax Expense | $0 | $0 | $0 | -$0 |
| Net Income | -$8 | -$16 | -$11 | -$8 |
| % Margin | -150.8% | -709.9% | -409.2% | -144% |
| EPS | 0.26 | -0.52 | -0.36 | -0.19 |
| % Growth | 150% | -44.4% | -89.5% | – |
| EPS Diluted | 0.26 | -0.52 | -0.36 | -0.19 |
| Weighted Avg Shares Out | 30 | 30 | 30 | 26 |
| Weighted Avg Shares Out Dil | 30 | 30 | 30 | 26 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | -$2 |
| Interest Expense | – | $0 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $1 |
| EBITDA | -$8 | -$14 | -$11 | -$12 |
| % Margin | -145.8% | -618% | -419.8% | -226.3% |